Brensocatib

Brensocatib

Definition

An orally bioavailable, small molecule, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), with potential anti-inflammatory activity. Upon oral administration, brensocatib reversibly binds to and inhibits the activity of DPP1, thereby inhibiting the activation of neutrophil serine proteases (NSPs), including neutrophil elastase (NE), during neutrophil maturation. This inhibits the activity of NSPs, and may prevent lung inflammation and injury and improve lung function associated with NSPs-induced respiratory diseases. NSPs, serine proteases released by neutrophils during inflammation, is upregulated in a number of respiratory diseases.

Also known as AZD 7986, AZD-7986, AZD7986, BRENSOCATIB, INS 1007, INS-1007, INS1007 — per NCIT

Also identified as

Indications

Disease Relation Source
Bronchiectasis may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Lungs may treat a disease of this organ DERIVED · CC BY 4.0
Respiratory system may treat a disease of this organ DERIVED · CC BY 4.0

2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.